ASH 2020 | Real-world results of an in-class transition from VRd to IRd in myeloma

Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, reports the efficacy and safety results of a study (NCT03173092) investigating a transition from parenteral bortezomib-based treatment to oral ixazomib-based treatment (ixazomib-lenalidomide-dexamethasone) (IRd) for multiple myeloma patients. While beneficial to outcomes, long-term parenteral proteasome inhibitor treatment can be burdensome due to intravenous administration, requirement for hospital-based treatment, and toxicity. The study assessed an in-class transition, hoping to increase treatment duration whilst maintaining quality of life. Of the 101 patients enrolled to date, mean therapy duration was over 1-year, and the overall response rate increased from 62% after bortezomib induction, to 71% on IRd. The results demonstrate the utility and tolerability of an in-class transition which improved treatment duration and responses in a community setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020